Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

info@bullrun.co.in

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

  1. Home
  2. /
  3. Sectors
  4. /
  5. Healthcare Research, Analytics & Technology
  6. /
  7. Vimta Labs Ltd
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsBalance SheetProfit & LossCash Flow
HomeStocksHealthcare Research, Analytics & TechnologyVimta Labs Ltd

Vimta Labs Ltd Stock Price Today (NSE: VIMTALABS)

Vimta Labs Ltd

VIMTALABSHealthcare Research, Analytics & Technology
₹380.70+₹0.00 (+0.00%)↑
As on 30 Mar 2026, 12:07 pm ISTMarket Closed

Fundamental Score

...

Vimta Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Vimta Labs Ltd share price today is ₹380.70, up +0.00% on NSE/BSE as of 30 March 2026. Vimta Labs Ltd (VIMTALABS) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹2.72K (Cr). The 52-week high for VIMTALABS share price is ₹902.65 and the 52-week low is ₹395.80. At a P/E ratio of 36.39x, VIMTALABS is currently trading below its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 19.43% and a debt-to-equity ratio of 0.02.

Vimta Labs Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.00%

Returns & Performance

Good

ROE

19.43%
Excellent

ROCE

25.22%
Excellent

OPM (5Y)

30.85%

Div Yield

0.16%

Vimta Labs Ltd Valuation Check

Good

P/E Ratio

36.39x
Poor

Industry P/E

45.95x
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Market Cap

2.72K (Cr)

Growth Engine

Good

Profit Growth (Q)

17.04%
Excellent

Sales Growth (Q)

20.19%
Excellent

Sales Growth (5Y)

13.74%
Excellent

EPS Growth (5Y)

57.82%
Excellent

Profit Growth (5Y)

58.03%

Balance Sheet Health

Excellent

Debt to Equity

0.02x
Excellent

Int. Coverage

59.75x

Free Cash Flow (5Y)

65.94 (Cr)

Shareholding

Excellent

Promoter

35.99%
Poor

FII

4.33%
Poor

DII

0.87%
Excellent

Pledged

0.00%

Institutional Deep-Dive

Bull Run Research Hub

Vimta Labs Share Price Analysis: A ROCE-Driven Perspective on Healthcare Research

In the dynamic landscape of Healthcare Research, Analytics & Technology, agility and efficient capital allocation are paramount. Investors closely watch companies that can generate strong returns on capital employed. This analysis examines the recent performance of Vimta Labs share price, currently trading at ₹423.70, through the lens of Return on Capital Employed (ROCE) efficiency. A high ROCE often indicates a company's ability to generate profits from its investments, a critical factor in long-term value creation.

Vimta Labs' ROCE stands at a noteworthy 25.22%. This metric is crucial as it illustrates how effectively the company is using its capital to generate profits. A higher ROCE generally indicates a stronger competitive advantage and potentially a wider economic moat. Vimta's ability to consistently generate such returns suggests effective resource allocation and operational efficiency. This translates into greater financial flexibility, allowing the company to potentially reinvest in growth initiatives, fund acquisitions, or return value to shareholders.

Comparing Vimta Labs with its peers provides a more nuanced understanding. While a direct comparison with NOVELIX PHARMACEUTICALS LIMITE requires detailed analysis of management quality and strategic direction, the ROCE differential can offer initial insights. For instance, if Novelix Pharmaceuticals exhibits a significantly lower ROCE, it may suggest differing levels of operational efficiency or capital allocation strategies. Such differences could stem from variations in management expertise and decision-making prowess, ultimately impacting shareholder returns. However, a holistic comparison would require deeper investigation into factors like asset turnover and profit margins.

The 25.22% ROCE directly strengthens Vimta Labs' economic moat. It enables the company to reinvest profits at high rates, creating a virtuous cycle of growth and profitability. This high ROCE makes it more challenging for competitors to replicate Vimta's business model, as they would need to achieve similar levels of efficiency and returns. A sustainable competitive advantage built on ROCE efficiency can lead to sustained superior performance over the long term.

Disclaimer: This analysis is purely observational and based on publicly available information as of the date of this report. No investment recommendations are made. This analysis forms part of an 80-parameter fundamental audit, verified by Sweta Mishra, focusing on financial performance metrics like ROCE.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Vimta Labs Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of VIMTALABS across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (19.43%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (25.22%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (30.85%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 36.39 vs Industry: 45.95)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (20.19%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (13.74% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (57.82% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (58.03% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (59.75x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹65.94 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 5.20%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Vimta Labs Ltd Financial Statements

Comprehensive financial data for Vimta Labs Ltd including income statement, balance sheet and cash flow

About VIMTALABS (Vimta Labs Ltd)

Vimta Labs Ltd is a pioneering force within the healthcare research, analytics, and technology landscape, providing a comprehensive suite of services that underpin the advancement ...of medical science and patient care. The company distinguishes itself through its commitment to rigorous scientific methodology, cutting-edge technologies, and a team of highly skilled professionals dedicated to driving innovation. From meticulously designed preclinical studies to expertly managed clinical trials and sophisticated analytical investigations, Vimta Labs serves as a strategic partner for biopharmaceutical companies, medical device manufacturers, and organizations navigating the complexities of healthcare product development. Its focus extends to ensuring the safety and efficacy of healthcare products, empowering its clients to bring innovative solutions to market with confidence. The capabilities of Vimta Labs span the entire healthcare product lifecycle, encompassing early-stage research, clinical development, and post-market surveillance. Employing advanced technologies in genomics, proteomics, and bioinformatics, the company extracts meaningful insights from complex data, accelerating drug discovery and personalized medicine approaches. Their analytical prowess extends to comprehensive quality control and regulatory compliance, helping clients to navigate the intricate web of industry regulations. By combining deep scientific expertise with sophisticated analytical tools, Vimta Labs contributes to informed decision-making, optimized product development strategies, and improved patient outcomes. Its commitment to rigorous testing and insightful data analysis makes it a valuable partner for businesses seeking to ensure the success of their healthcare products. Beyond traditional laboratory services, Vimta Labs embraces technological advancements to enhance its capabilities and deliver integrated solutions. The company leverages sophisticated data analytics platforms, artificial intelligence, and machine learning algorithms to extract valuable insights from large datasets, accelerating research and optimizing clinical trial design. By seamlessly integrating technology with its scientific expertise, Vimta Labs fosters innovation, drives efficiency, and provides its clients with a competitive edge. With a steadfast dedication to scientific excellence, technological innovation, and client satisfaction, Vimta Labs continues to be a trusted partner for companies seeking to transform healthcare through research, analytics, and advanced technology.

Company Details

Symbol:VIMTALABS
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology
Website:https://vimta.com

Key Leadership

Dr. Sivalinga Prasad Vasireddi
Executive Chairman
Ms. Harita Vasireddi
MD & Whole Time Director
Mr. Siva Rama Krishna Kambhampati
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date
2025-05-30

VIMTALABS Share Price: Frequently Asked Questions

What is the current share price of Vimta Labs Ltd (VIMTALABS)?

As of 30 Mar 2026, 12:07 pm IST, Vimta Labs Ltd share price is ₹380.70. The VIMTALABS stock has a market capitalisation of ₹2.72K (Cr) on NSE/BSE.

Is VIMTALABS share price Overvalued or Undervalued?

VIMTALABS share price is currently trading at a P/E ratio of 36.39x, compared to the industry average of 45.95x. Based on this relative valuation, the Vimta Labs Ltd stock appears to be Undervalued against its sector peers.

What is the 52-week high and low of VIMTALABS share price?

The 52-week high of VIMTALABS share price is ₹902.65 and the 52-week low is ₹395.80. These values are updated daily from NSE/BSE price data.

What factors affect the Vimta Labs Ltd share price?

Key factors influencing VIMTALABS share price include quarterly earnings growth (Sales Growth: 20.19%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Vimta Labs Ltd a good stock for long-term investment?

Vimta Labs Ltd shows a 5-year Profit Growth of 58.03% and an ROE of 19.43%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in VIMTALABS shares.

How does Vimta Labs Ltd compare with its industry peers?

Vimta Labs Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare VIMTALABS share price P/E of 36.39x and ROE of 19.43% against the industry averages to determine competitive standing.

What is the P/E ratio of VIMTALABS and what does it mean?

VIMTALABS share price has a P/E ratio of 36.39x compared to the industry average of 45.95x. Investors pay ₹36 for every ₹1 of annual earnings.

How is VIMTALABS performing according to Bull Run's analysis?

VIMTALABS has a Bull Run fundamental score of 65.8/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does VIMTALABS belong to?

VIMTALABS operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vimta Labs Ltd share price.

What is Return on Equity (ROE) and why is it important for VIMTALABS?

VIMTALABS has an ROE of 19.43%, which indicates excellent management efficiency. ROE measures how efficiently Vimta Labs Ltd generates profits from shareholders capital.

How is VIMTALABS debt-to-equity ratio and what does it indicate?

VIMTALABS has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.

What is VIMTALABS dividend yield and is it a good dividend stock?

VIMTALABS offers a dividend yield of 0.16%, meaning you receive ₹0.16 annual dividend for every ₹100 invested in Vimta Labs Ltd shares.

How has VIMTALABS share price grown over the past 5 years?

VIMTALABS has achieved 5-year growth rates of: Sales Growth 13.74%, Profit Growth 58.03%, and EPS Growth 57.82%.

What is the promoter holding in VIMTALABS and why does it matter?

Promoters hold 35.99% of VIMTALABS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vimta Labs Ltd.

What is VIMTALABS market capitalisation category?

VIMTALABS has a market capitalisation of ₹2717 crores, placing it in the Small-cap category.

How volatile is VIMTALABS stock?

VIMTALABS has a beta of N/A. A beta > 1 suggests the Vimta Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is VIMTALABS operating profit margin trend?

VIMTALABS has a 5-year average Operating Profit Margin (OPM) of 30.85%, indicating the company's operational efficiency.

How is VIMTALABS quarterly performance?

Recent quarterly performance shows Vimta Labs Ltd YoY Sales Growth of 20.19% and YoY Profit Growth of 17.04%.

What is the institutional holding pattern in VIMTALABS?

VIMTALABS has FII holding of 4.33% and DII holding of 0.87%. Significant institutional holding often suggests professional confidence in the Vimta Labs Ltd stock.

HomeScreenerBattleWatchlist

Frequently Asked Questions about Vimta Labs Ltd

What is the current share price of Vimta Labs Ltd?

Vimta Labs Ltd (VIMTALABS) trades at ₹380.70 on NSE and BSE. Market cap ₹2.72K (Cr). Educational data only.

What is the P/E ratio of Vimta Labs Ltd?

Vimta Labs Ltd has a P/E of 36.39x vs industry average 45.95x.

What is the Bull Run score for Vimta Labs Ltd?

Vimta Labs Ltd has a Bull Run score of 65.8/100 based on 25+ financial parameters.

Does Vimta Labs Ltd pay dividends?

Vimta Labs Ltd has a dividend yield of 0.16%. Past dividends don't guarantee future payments.

What is the ROE of Vimta Labs Ltd?

Vimta Labs Ltd has ROE of 19.43%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Vimta Labs Ltd?

Vimta Labs Ltd has debt-to-equity of 0.02.

Is Vimta Labs Ltd a good investment?

Bull Run gives Vimta Labs Ltd a score of 65.8/100. This is not investment advice — consult a SEBI-registered advisor.